Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-016892
Filing Date
2021-02-09
Accepted
2021-02-09 21:17:57
Documents
2
Period of Report
2021-02-09

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm214979-5_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm214979-5_3seq1.xml 3 3669
2 EXHIBIT 24 tm214979d5_ex-24.htm EX-24 6902
  Complete submission text file 0001104659-21-016892.txt   12009
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Issuer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 100 N. 18TH STREET SUITE 300 PHILADELPHIA PA 19103
Business Address
Baker David Charles (Reporting) CIK: 0001844060 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40034 | Film No.: 21608869